Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech Announces Four Senior Appointments in Development and Product Operations

South San Francisco, Calif. -- November 7, 2001 --

Genentech, Inc. (NYSE: DNA) today announced four senior appointments in the company's Development and Product Operations organizations.

"These promotions reflect Genentech's continued commitment to discovering, developing and manufacturing the highest quality medicines for patients with unmet medical needs," said Susan D. Hellmann, M.D., M.P.H., executive vice president, Development and Product Operations, and chief medical officer. "These individuals have achieved impressive results in their respective areas, and have the knowledge and leadership required to help us achieve Genentech's long-term growth goals."

Paula Jardieu, Ph.D., 49, is promoted to senior vice president, Development Sciences. Jardieu joined Genentech in 1986 and has played a key role in the research and development of several therapeutic projects. Most recently, she held the title of vice president, Development Sciences. In her new role, Jardieu is responsible for leading development efforts in Analytical Sciences, Clinical and Experimental Pharmacology, Process Sciences, and Safety Assessment.

Ronald Branning, 55, joined Genentech as vice president, Global Quality, in September 2001. Branning is responsible for leading the company's Quality organization including quality assurance and quality control of all of Genentech's clinical and marketed products. Branning most recently held the position of vice president of Quality Operations at Aventis Behring.

Frank Jackson, 53, is promoted to vice president, Vacaville Product Operations. Jackson has been with Genentech since 1981, when he joined the company as manager of Fermentation Operations and Technical Services in South San Francisco. In 1994, he became general manager of Genentech's Vacaville facility. In his new position, Jackson continues to lead Genentech's manufacturing facility in Vacaville, one of the most productive protein pharmaceutical facilities in the world.

Bernice Welles, M.D., 49, is promoted to vice president, Product Development. Welles joined Genentech as a clinical scientist in 1995. She became director of the Specialty Therapeutics Unit in 1998, and was promoted to senior director of this unit in 2000. In her new role, Welles is responsible for driving Genentech's strategic drug development efforts.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fifteen of the currently approved products of biotechnology are based on or stem from Genentech science. Genentech markets ten products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.